As of April 29, 2025, Cel-Sci (CVM) has a market cap of $24.396 million USD. According to our data, Cel-Sci is ranked No.8482 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 29, 2025 | $24.40 M |
-17.70%
|
Dec 31, 2024 | $29.64 M |
-85.29%
|
Dec 29, 2023 | $0.20 B |
15.74%
|
Dec 30, 2022 | $0.17 B |
-66.90%
|
Dec 31, 2021 | $0.53 B |
-39.11%
|
Dec 31, 2020 | $0.86 B |
27.43%
|
Dec 31, 2019 | $0.68 B |
218.82%
|
Dec 31, 2018 | $0.21 B |
51.85%
|
Dec 29, 2017 | $0.14 B |
8.00%
|
Dec 30, 2016 | $0.13 B |
-81.08%
|
Dec 31, 2015 | $0.69 B |
-36.21%
|
Dec 31, 2014 | $1.07 B |
-1.69%
|
Dec 31, 2013 | $1.09 B |
-78.15%
|
Dec 31, 2012 | $5.00 B |
-6.90%
|
Dec 30, 2011 | $5.37 B |
-64.63%
|
Dec 31, 2010 | $15.19 B |
-8.89%
|
Dec 31, 2009 | $16.67 B |
210.34%
|
Dec 31, 2008 | $5.37 B |
-43.14%
|
Dec 31, 2007 | $9.45 B |
-8.93%
|
Dec 29, 2006 | $10.37 B |
14.29%
|
Dec 30, 2005 | $9.08 B |
-18.33%
|
Dec 31, 2004 | $11.12 B |
-43.40%
|
Dec 31, 2003 | $19.64 B |
404.76%
|
Dec 31, 2002 | $3.89 B |
-77.89%
|
Dec 31, 2001 | $17.60 B |
-36.67%
|
Dec 29, 2000 | $27.79 B |
-35.14%
|
Dec 31, 1999 | $42.84 B |
32.14%
|
Dec 31, 1998 | $32.42 B |
-73.58%
|
Dec 31, 1997 | $122.74 B |
55.88%
|
Dec 31, 1996 | $78.74 B |
18.26%
|
Dec 29, 1995 | $66.58 B |
-11.54%
|
Dec 30, 1994 | $75.26 B |
-71.74%
|
Dec 31, 1993 | $266.32 B |
-24.59%
|
Dec 31, 1992 | $353.17 B |
-40.20%
|
Dec 31, 1991 | $590.54 B |
410.00%
|
Dec 31, 1990 | $115.79 B |
25.00%
|
Dec 29, 1989 | $92.63 B |
-20.00%
|
Dec 30, 1988 | $115.79 B |
-73.68%
|
Dec 31, 1987 | $440.01 B |
-38.71%
|
Dec 31, 1986 | $717.91 B |
121.43%
|
Dec 31, 1985 | $324.22 B |
180.00%
|
Dec 31, 1984 | $115.79 B |
-28.57%
|
Dec 30, 1983 | $162.11 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Amgen
AMGN
|
$152.20 B |
0.126 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$132.39 B |
-0.001 M
|
![]() USA
|
![]() Regeneron Pharmaceuticals
REGN
|
$62.20 B |
1.034 B
|
![]() USA
|
![]() Biogen
BIIB
|
$17.59 B |
0.000 M
|
![]() USA
|
![]() Moderna
MRNA
|
$10.76 B |
0.000 M
|
![]() USA
|
![]() Novavax
NVAX
|
$1.03 B |
0.000 M
|
![]() USA
|
![]() Inovio Pharmaceuticals
INO
|
$70.05 M |
0.000 M
|
![]() USA
|
![]() BioNTech
BNTX
|
$25.00 B |
0.001 M
|
![]() Germany
|
![]() Vertex Pharmaceuticals
VRTX
|
$127.64 B |
0.004 M
|
![]() USA
|
![]() Pfizer
PFE
|
$130.73 B |
-0.001 M
|
![]() USA
|
![]() Merck
MRK
|
$212.01 B |
-0.001 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$375.13 B |
0.006 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$98.62 B |
0.002 M
|
![]() USA
|
![]() Eli Lilly
LLY
|
$794.90 B |
-0.026 M
|
![]() USA
|
![]() AstraZeneca
AZN
|
$222.30 B |
0.004 M
|
![]() UK
|
Market Cap | = | CVM Stock Price | * | CVM Shares Outstanding |
= | $0.29 | * | 84.12 M | |
= | $24.40 M |